NDA 12-380/S-022/S-023/025

Parke-Davis Pharmaceutical Research
Division of Warner-Lambert Company
Attention: Phil Simonson, Ph.D.
Director, Regulatory Affairs
2800 Plymouth Road, P.O. Box 1047
Ann Arbor, MI 48106-1047

09 APR 2001

Dear Dr. Simonson:

Please refer to your supplemental new drug applications dated September 6, 1989 (S-022), June 14, 1991 (S-023), and November 22, 1996 (S-025) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zarontin (ethosuximide) 250 mg Capsules and 250 mg/5 ml Syrup.

We additionally acknowledge receipt of your amendment dated September 29, 1989 to S-022.

These supplemental applications provide for the following revisions to the Zarontin labeling:

S-022

1. Change the section name from **ACTION** to **CLINICAL PHARMACOLOGY**.
2. Change the section name from **INDICATION** to **INDICATIONS AND USAGE**.
3. Under the **WARNINGS** section, add the following sentence, "Should signs and/or symptoms of infection (e.g., sore throat, fever) develop, blood counts should be considered at that point".
4. Under the section **PRECAUTIONS-Usage in Pregnancy**, the deletion of the first line and the word "Recent" from the first line of the second paragraph.
5. The subsection **Hazardous Duties** under the **WARNINGS** section has been deleted, and it is included as the first paragraph in a new subsection entitled **Information for Patients** under the **PRECAUTIONS** section.
6. In the **PRECAUTIONS** section, the addition of the subsection entitled **General** for the first paragraph.
7. The addition of a new subsection entitled **Pregnancy** under the **PRECAUTIONS** section referencing the prescriber to the **WARNINGS** section.
8. The addition of a new subsection entitled **Drug Interactions** under the **PRECAUTIONS** section.
9. The revision of the subsections **Gastrointestinal System** and **Hemopoietic System** and the addition of 2 new subsections entitled **Special Senses** and **Genitourinary System** under the **ADVERSE REACTIONS** section.
10. The deletion of the subsection **Miscellaneous** under the **ADVERSE REACTIONS** section, and placement of this information under the **Gastrointestinal**, **Integumentary**, **Special Senses**, and **Genitourinary System** subsections.
11. The addition of a new **OVERDOSAGE** section .

S-023
The addition of the terms "microscopic hematuria" in the **ADVERSE REACTIONS-Genitourinary System** section of labeling as requested in an Agency letter dated September 13, 1990.

S-025
The addition of a new subsection entitled **Pediatric Use** under the **PRECAUTIONS** section.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted November 22, 1996-Label Code 0237G027), which incorporates the revisions listed above. Accordingly, these supplemental applications are approved effective on the date of this letter.

Labeling changes of the kind which you have proposed under the above supplemental applications are permitted by section 314.70(c) of the regulations to be instituted prior to approval of the supplement. It is understood that the changes, described in the above NDA supplements, have been made.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Mr. Paul David, R.Ph., Senior Regulatory Project Manager, at (301) 594-5530.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research